Initial high-efficacy disease-modifying therapy in multiple sclerosisMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2020Cited by 160
Progressive multiple sclerosis, cognitive function, and quality of lifeHelene Højsgaard Chow, Finn Sellebjerg, Cecilie Ammitzbøll et al.|Brain and Behavior|2018Cited by 94
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trialKaren Schreiber, Per Soelberg Sørensen, Melinda Magyari et al.|Multiple Sclerosis Journal|2016Cited by 53
NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosisCecilie Ammitzbøll, Finn Sellebjerg, Tim B. Dyrby et al.|Multiple Sclerosis and Related Disorders|2023Cited by 13
Disability in progressive MS is associated with T2 lesion changesCecilie Ammitzbøll, Finn Sellebjerg, Tim B. Dyrby et al.|Multiple Sclerosis and Related Disorders|2017Cited by 10